UNSPSC 51381507: Talosalate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H12O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1356SD6O2G, chemically known as salicylic acid acetate, ester with 3-hydroxyphthalide but generally known as talosalate, which bears US NIH Compound Identifier 68558. European Medicines Agency schedules Talosalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10812MIG.

UNSPSC 51381507 Talosalate, a Commodity code, nominally identifies a specific anti-inflammatory drug, but recent state and local procurement activity under this code reflects a much broader scope: counties and state health agencies are sourcing naloxone, pharmaceutical products, and drug deactivation systems through competitive bidding and cooperative purchasing agreements. The work involves establishing supply contracts for emergency medical supplies, generic pharmaceuticals, and over-the-counter products distributed across public health facilities, with vendors responsible for meeting cGMP and Drug Supply Chain Security Act compliance, maintaining authorized wholesaler relationships, and fulfilling quarterly or continuous delivery schedules. Issuing bodies include county health departments (Seminole County, Florida) and state health and human services agencies (Texas HHS Commission) participating in multistate cooperative purchasing alliances such as MMCAP, which coordinates procurement across member jurisdictions including Minnesota and Oregon.

Recent activity spans Florida, Texas, and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (likely a data entry error in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling future formal procurement on pharmaceutical supply. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, evaluation weighted 75 percent on price competitiveness, and contract term of two years effective July 1, 2026. Vendors must maintain commercial general liability of $5,000,000 per occurrence and comply with FDA requirements, authorized wholesaler networks, and a 3 percent administrative fee on all contract purchases.